FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3033530857> ?p ?o ?g. }

• W3033530857 abstract "Abstract Background and Aims The diagnostic utility of ANCA antibodies in ANCA associated-vasculitis (AAV), antiproteinase 3 (PR3) and myeloperoxidase (MPO) testing is now undisputed, but the clinical utility of serial MPO/PR3 testing to predict relapses, remain controversial. The aim of this study was to analyze the relevance of serum MPO and PR3 antibody level assessment in the management of AAV. We sought to determine whether MPO and PR3 antibody levels correlated with renal disease activity, and whether an increase could predict a nephritis flare. Method Retrospective multicenter study including AAV-patients with renal involvement from 7 nephrology departments belonging to the Spanish Glomerular Study Group (GLOSEN). The main inclusion criteria were that MPO antibodies were detected by ELISA (Multiplex assay) and PR3 using chemioluminescence immunoassay. For statistical purpose a continuous variable were calculated, called delta MPO/PR3(ΔMPO y ΔPR3) that reflects change in antibodies levels 6 months before renal flare. Clinical data were recorded since complete remission of first nephritis diagnosis flare until second renal relapse. Results 113 AAV-patients with pauci-inmune necrotizing glomerulonephritis were included, 59 (52.2%) women, mean age (64.3±14.8 years), 85 patients (75.2%) MPO-AAV and 28 (24.8%) PR3-AAV, after a mean follow-up of 5±4.8 years, 54 renal relapses occurred in 40 (52,6%) MPO-AAV patients and in 14 (57.1%) PR3-AAVpatients. Serum MPO levels were significant higher in relapser-patients compared with non- relapser patients, 3±1.2 months before nephritis relapse [(n=32) 19.2±12.2 IA vs (n=38) 3.2±5.1 IA, p&lt;0.001)]. Δ MPO levels were significant higher in relapse-patients compared with non-relapser patients [(n=32) 8.3±12 IA vs (n=38) 0.9±3.1.1 IA, p=0.001). The discrimination value of the MPO antibody levels 3 months before renal relapse were established by means of a ROC curve: AUC of 0.82 (95% CI 0.73 to 0.92; p&lt;0.001) and the MPO cut-off value predicting renal relapse were established in 8.3 IA. The discrimination value of the ΔMPO were established by means of ROC curve: AUC of 0.76 (95% CI 0.63 to 0.88; p&lt;0.001), ΔMPO cut-off value were established in an increase of MPO levels of 3.7 IA. Serum PR3 levels were significant higher in relapser-patients 2.8±1.4 months before relapse [(n=14) 58.6±6.6 IA vs (n=7) 2.0±0.6 IA, p&lt;0.001)] and Δ PR3 levels were significant higher in relapse-patients compared with non-relapser patients [(n=14) 57.5±28.5 IA vs (n=7) 0.8±0.2. IA, p&lt;0.001)]. The discrimination value of the PR3 3 months before flare and Δ PR3 antibody levels were established by means of ROC curve: AUC 1. Conclusion Our results show that MPO antibodies, measured by Multiplex assay, could be a useful predictor of glomerulonephritis flare in AAV-patients. MPO levels 3 months before renal flare seems a good marker confirmed by ROC curve results, MPO cut-off value with the best sensitivity and specificity in predicting renal relapse was established in 8.3 IA. Δ MPO levels show that increase in titers ≥ 3.7 IA 6 months before renal flare, predict nephritis relapse However, PR3 antibodies are not a useful predictor marker, rise in antibodies level indicate renal vasculitis activity." @default.
• W3033530857 created "2020-06-12" @default.
• W3033530857 creator A5001003063 @default.
• W3033530857 creator A5004108111 @default.
• W3033530857 creator A5008472624 @default.
• W3033530857 creator A5015361378 @default.
• W3033530857 creator A5019998877 @default.
• W3033530857 creator A5052211865 @default.
• W3033530857 creator A5062073237 @default.
• W3033530857 creator A5068167968 @default.
• W3033530857 creator A5073873354 @default.
• W3033530857 creator A5076941359 @default.
• W3033530857 creator A5076952603 @default.
• W3033530857 creator A5079406839 @default.
• W3033530857 creator A5080926563 @default.
• W3033530857 creator A5083034201 @default.
• W3033530857 creator A5090121520 @default.
• W3033530857 date "2020-06-01" @default.
• W3033530857 modified "2023-10-16" @default.
• W3033530857 title "MO038ANTIMYELOPEROXIDASE AND PROTEINASE 3 ANTIBODIES ARE A USEFUL MARKER AS NEPHRITIS FLARE PREDICTOR IN ANCA-ASSOCIATED VASCULITIS" @default.
• W3033530857 doi "https://doi.org/10.1093/ndt/gfaa140.mo038" @default.
• W3033530857 hasPublicationYear "2020" @default.
• W3033530857 type Work @default.
• W3033530857 sameAs 3033530857 @default.
• W3033530857 citedByCount "0" @default.
• W3033530857 crossrefType "journal-article" @default.
• W3033530857 hasAuthorship W3033530857A5001003063 @default.
• W3033530857 hasAuthorship W3033530857A5004108111 @default.
• W3033530857 hasAuthorship W3033530857A5008472624 @default.
• W3033530857 hasAuthorship W3033530857A5015361378 @default.
• W3033530857 hasAuthorship W3033530857A5019998877 @default.
• W3033530857 hasAuthorship W3033530857A5052211865 @default.
• W3033530857 hasAuthorship W3033530857A5062073237 @default.
• W3033530857 hasAuthorship W3033530857A5068167968 @default.
• W3033530857 hasAuthorship W3033530857A5073873354 @default.
• W3033530857 hasAuthorship W3033530857A5076941359 @default.
• W3033530857 hasAuthorship W3033530857A5076952603 @default.
• W3033530857 hasAuthorship W3033530857A5079406839 @default.
• W3033530857 hasAuthorship W3033530857A5080926563 @default.
• W3033530857 hasAuthorship W3033530857A5083034201 @default.
• W3033530857 hasAuthorship W3033530857A5090121520 @default.
• W3033530857 hasBestOaLocation W30335308571 @default.
• W3033530857 hasConcept C126322002 @default.
• W3033530857 hasConcept C159654299 @default.
• W3033530857 hasConcept C203014093 @default.
• W3033530857 hasConcept C203565725 @default.
• W3033530857 hasConcept C21194631 @default.
• W3033530857 hasConcept C2776015282 @default.
• W3033530857 hasConcept C2776914184 @default.
• W3033530857 hasConcept C2777058396 @default.
• W3033530857 hasConcept C2778653478 @default.
• W3033530857 hasConcept C2779134260 @default.
• W3033530857 hasConcept C2780420688 @default.
• W3033530857 hasConcept C54847362 @default.
• W3033530857 hasConcept C71924100 @default.
• W3033530857 hasConcept C90924648 @default.
• W3033530857 hasConceptScore W3033530857C126322002 @default.
• W3033530857 hasConceptScore W3033530857C159654299 @default.
• W3033530857 hasConceptScore W3033530857C203014093 @default.
• W3033530857 hasConceptScore W3033530857C203565725 @default.
• W3033530857 hasConceptScore W3033530857C21194631 @default.
• W3033530857 hasConceptScore W3033530857C2776015282 @default.
• W3033530857 hasConceptScore W3033530857C2776914184 @default.
• W3033530857 hasConceptScore W3033530857C2777058396 @default.
• W3033530857 hasConceptScore W3033530857C2778653478 @default.
• W3033530857 hasConceptScore W3033530857C2779134260 @default.
• W3033530857 hasConceptScore W3033530857C2780420688 @default.
• W3033530857 hasConceptScore W3033530857C54847362 @default.
• W3033530857 hasConceptScore W3033530857C71924100 @default.
• W3033530857 hasConceptScore W3033530857C90924648 @default.
• W3033530857 hasLocation W30335308571 @default.
• W3033530857 hasOpenAccess W3033530857 @default.
• W3033530857 hasPrimaryLocation W30335308571 @default.
• W3033530857 hasRelatedWork W11453199 @default.
• W3033530857 hasRelatedWork W13927973 @default.
• W3033530857 hasRelatedWork W15917550 @default.
• W3033530857 hasRelatedWork W16987333 @default.
• W3033530857 hasRelatedWork W19802325 @default.
• W3033530857 hasRelatedWork W20079048 @default.
• W3033530857 hasRelatedWork W21323388 @default.
• W3033530857 hasRelatedWork W7755818 @default.
• W3033530857 hasRelatedWork W8532307 @default.
• W3033530857 hasRelatedWork W9641291 @default.
• W3033530857 isParatext "false" @default.
• W3033530857 isRetracted "false" @default.
• W3033530857 magId "3033530857" @default.
• W3033530857 workType "article" @default.